公司资料
Avalo Therapeutics 股价、新闻与催化剂
- 股票代码:
- AVTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
19.27 USD (-2.82%)
收盘价
最后更新: 2026年8月24日
734M USD
市值
股价为何变动
As of Aug 24, 2026, AVTX closed down 2.82% at $19.27. No new same-company headline was identified in the current news window.
公司概览
Clinical Immunology Company
Avalo Therapeutics develops therapies for immune-mediated inflammatory diseases.
Abdakibart
Abdakibart is an antibody targeting IL-1β and is being developed for moderate-to-severe hidradenitis suppurativa.
LOTUS Evidence
The Phase 2 LOTUS study met its primary endpoint at both evaluated doses, supporting advancement into registrational development.
未来催化剂
- Avalo plans to advance abdakibart into a Phase 3 registrational program in hidradenitis suppurativa.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。